Research Progress of Post-Transplant Cyclophosphamide Combined with Antithymocyte Globulin in Preventing GVHD after Hematopoietic Stem Cell Transplantation --Review.
10.19746/j.cnki.issn.1009-2137.2023.06.047
- Author:
Meng-Jie WU
1
;
Pei-Pei YE
2
Author Information
1. Health Science Center, Ningbo University, Ningbo 315211, Zhejiang Province, China.
2. Department of Hematology, The Affiliated Hospital of Health Science Center, Ningbo University, Ningbo 315100, Zhejiang Province, China E-mail: 39612903@qq.com.
- Publication Type:Journal Article
- Keywords:
post-transplant cyclophosphamide;
anti-thymic globulin;
graft-versus-host disease;
hematopoietic stem cell transplantation
- MeSH:
Humans;
Antilymphocyte Serum;
Cyclophosphamide;
Hematopoietic Stem Cell Transplantation/adverse effects*;
Graft vs Host Disease/prevention & control*;
Transplantation, Homologous;
Retrospective Studies
- From:
Journal of Experimental Hematology
2023;31(6):1899-1904
- CountryChina
- Language:Chinese
-
Abstract:
Graft-versus-host disease (GVHD) is one of the major complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT), which seriously affects the prognosis of patients. At present, a new regimen of post-transplantation cyclophosphamide (PTCy) combined with antithymocyte globulin (ATG) has been used to prevent GVHD, indicating that PTCy combined with ATG may have a good effect on the prevention of GVHD in different types of transplantation. However, the mechanism of this regimen, its effect on immune reconstitution and viral reactivation still needs to be further studied. Therefore, this article briefly reviews the research progress of PTCy combined with ATG in preventing GVHD after HSCT.
